Author:
Olsen David B.,Davies Mary-Ellen,Handt Larry,Koeplinger Kenneth,Zhang Nanyan Rena,Ludmerer Steven W.,Graham Donald,Liverton Nigel,MacCoss Malcolm,Hazuda Daria,Carroll Steven S.
Abstract
ABSTRACTEfforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are contingent on the ability of combination therapies consisting of direct antiviral inhibitors to achieve a sustained virologic response. This work demonstrates a proof of concept that coadministration of the nucleoside analogue MK-0608 with the protease inhibitor MK-7009, both of which produced robust viral load declines as monotherapy, to an HCV-infected chimpanzee can achieve a cure of infection.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference10 articles.
1. Carroll, S. S., Ludmerer, et al. 2009. Robust antiviral efficacy upon administration of a nucleoside analog to Hepatitis C Virus-infected chimpanzees. Antimicrob. Agents Chemother. 53:926-934.
2. Fried, M. W., et al. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36:S237-S244.
3. Fujii, H., et al. 2010. Relapse of hepatitis C in a pegylated-interferon-a-wb plus ribavirin-treated sustained virological responder. Hepatol. Res. 40:654-660.
4. Gane, E. J., et al. 2009. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1, abstr. 193. 60th Annu. Meet. Am. Assoc. Study Liver Dis., Boston, MA, 30 October to 1 November 2009.
5. Liverton, N. J., et al. 2010. MK-7009, a potent and selective inhibitor of Hepatitis C Virus NS3/4A protease. Antimicrob. Agents Chemother. 54:305-311.
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献